Journal of Diseases and Medicinal Plants

Submit a Manuscript

Publishing with us to make your research visible to the widest possible audience.

Propose a Special Issue

Building a community of authors and readers to discuss the latest research and develop new ideas.

Extract from Cistus × Incanus L. Pandalis also Effective Against “British” Alpha (B.1.1.7) and “South African” Beta (B.1.351) SARS-CoV-2 Variants

Background: In previous studies, a special extract from Cistus × incanus L. Pandalis (Cystus Pandalis® extract) has already proven to be effective against SARS-CoV-2 in vitro. We assume that an effect was also likely against the new SARS-CoV-2 variants, like the “British” alpha variant (B.1.1.7) as well as against the “South African” beta variant (B.1.351). Methods: To verify this, we investigated the inhibition of the cytopathic effect (CPE) of the coronaviruses by the Cystus Pandalis® extract in a cell model with human intestinal cells (Caco-2). We inoculated viral pre-treated cells with the herbal extract (A), and we mixed pre-treated viruses with the herbal extract in the cell cultures (B). Result: We observed an almost complete inhibition of virus growth by Cystus Pandalis® extract at concentrations of more than 100 μg/ml. The calculated IC50 (mean inhibitory concentration) for the “British” alpha variant (B.1.1.7) as well as for the “South African” beta variant (B.1.351) is below 50 μg/ml. There was no significant difference in the results in the two different ways of treatment. Conclusion: Extract from Cistus × incanus L. Pandalis (Cystus Pandalis® extract) can prevent in in-vitro cell cultures infections with SARS-CoV-2. Due to the high in vitro activity against the new variants, it also appears reasonable in the future to use Cystus Pandalis® as prophylaxis against infections with SARS-CoV-2. A development of resistance is unlikely. People tolerate the extract very well. It has no significant side effects.

Cystus Pandalis®, Virus Infection, SARS-CoV-2, Variants, Cistus Incanus

Jens-Martin Traeder. (2021). Extract from Cistus × Incanus L. Pandalis also Effective Against “British” Alpha (B.1.1.7) and “South African” Beta (B.1.351) SARS-CoV-2 Variants. Journal of Diseases and Medicinal Plants, 7(2), 44-47.

Copyright © 2021 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License ( which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. World Health Organisation: Weekly epidemiological update on COVID-19 - 23 March 2021,, last call on May 18th 2021.
2. Robert-Koch-Institut: Bericht zu Virusvarianten von SARS-CoV-2 in Deutschland, Stand 12. Mai 2021,, last call on May 18th 2021.
3. Jo, W. K., Drosten, C., & Drexler, J. The evolutionary dynamics of endemic human corona-viruses, Virus Evolution, Volume 7, Issue 1, January 2021, veab020,
4. Petereit F. Polyphenolische Inhaltsstoffe und Untersuchungen zur entzuendungshemmenden Aktivität der traditionellen Arzneipflanze Cistus incanus L. (Cistaceae). Dissertation, Universitaet Muenster, 1992.
5. Ehrhardt C, Hrincius ER, Korte V, Mazur I, Droebner K, et al. A polyphenol rich plant ex-tract, CYSTUS052, exerts anti influenza virus activity in cell culture without toxic side effects or the tendency to induce viral resistance. Antiviral research 2007, 76 (1), 38-47. doi: 10.1016/j.antiviral.2007.05.002.
6. Droebner K, Haasbach E, Mueller C, Ludwig S, & Planz O. The polyphenol rich plant ex-tract CYSTUS052 is highly effective against H5N1 and pandemic H1N1v influenza A virus. Influenza and Other Respiratory Viruses 2011, 5, 237-239. doi: 10.1111/j.1750-2659.2011.00209.x.
7. Droebner K, Ehrhardt C, Poetter A, Ludwig S, & Planz O. CYSTUS052, a polyphenol-rich plant extract, exerts anti-influenza virus activity in mice. Antiviral research 2007, 76 (1), 1-10. doi: 10.1016/j.antiviral.2007.04.001.
8. Ludwig S, Ehrhardt C, Haasbach E, Hrincius ER, Lapuse J, et al. Antiadhaesive Eigenschaften der Pflanzenextrakte Cystus052 und Ladania067 als breit wirksames antivirales Prinzip gegen respiratorische Viren. Zeitschrift fuer Phytotherapie 2013, 34 (S 01), P 19. doi: 10.1055/s-0033-1338221.
9. Rebensburg S, Helfer M, Schneider M, Koppensteiner H, Eberle J, et al. Potent in vitro antiviral activity of Cistus incanus extract against HIV and Filoviruses targets viral envelope proteins. Scientific reports 2016, 6, 20394. doi: 10.1038/srep20394.
10. Kalus U, Grigorov A, Kadecki O, Jansen JP, Kiesewetter H, et al. Cistus incanus (CYS-TUS052) for treating patients with infection of the upper respiratory tract: a prospective, randomised, placebo-controlled clinical study. Antiviral research 2009, 84 (3), 267-271. doi: 10.1016/j.antiviral.2009.10.001.
11. Adler M. Retrolektive Therapiebeobachtung im Rahmen der Pandemie mit Covid-19. Zeitschrift für Phytotherapie 2020; 41 (03): 111-112. doi: 10.1055/a-1102-1686.
12. Mhatre, S., Srivastava, T., Naik, S., & Patravale, V. Antiviral Activity of Green Tea and Black Tea Polyphenols in Prophylaxis and Treatment of COVID-19: A Review. Phytomed-icine 2020, 153286. doi: 10.1016/j.phymed.2020.153286.
13. Traeder, J. M.: Antivirale Eigenschaften des Extrakts aus Cistus × incanus L. Pandalis bei SARS-CoV-2 in vitro nachgewiesen. Erfahrungsheilkunde 2021; 70 (01): 59-62.
14. Kiesewetter, H. Cystussud zur lokalen Behandlung der Tonsillopharyngitis, Erfahrungsheilkunde 11/2002, S. 792-793.
15. Kiesewetter, H. Stellungnahme zu den beteiligten Viren bei den Cystus®-Studien von Kalus et al. 2009 und Kiesewetter 2002. Berlin, 10.05.2021.
16. Riehle, P. (2014). Phenolische Inhaltsstoffe in Cistus incanus Tee – Charakterisierung und Stabilität innerhalb der Teezubereitung, Dissertation, Universität Hamburg.